Companies › Shanghai Hengrui Pharmaceutical
15 active drug programs in 34 registered trials: 25 Phase 1, 7 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SHR-A2102 for Injection unclear - Shanghai Hengrui proprietary compound | – | Phase 3 | Advanced Urothelial Carcinoma; Advanced Solid Tumors; Non-small Cell Lung Cancer; Advanced or Metastatic Non-small Cell Lung Cancer | May 2027 |
| SHR-A1904 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Cancer; CLDN18.2-positive Advanced Solid Tumor | Sep 2027 |
| SHR-7787 Injection | – | Phase 2 | Limited-stage Small-cell Lung Cancer; Malignant Solid Tumors; Advanced Solid Tumors | Dec 2026 |
| Adebrelimab (SHR-1316) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 2 | Limited-stage Small-cell Lung Cancer; Malignant Solid Tumors; Advanced or Metastatic Non-small Cell Lung Cancer; Locally Advanced or Metastatic Pancreatic Cancer With … | Oct 2027 |
| BP102 Injection | – | Phase 2 | Malignant Solid Tumors | Dec 2028 |
| HRS8807 | – | Phase 1 | ER-Positive, HER2-Negative Breast Cancer | Dec 2026 |
| SHR6390 CDK4/6 inhibitor | CDK4, CDK6 | Phase 1 | ER-Positive, HER2-Negative Breast Cancer | Dec 2026 |
| SHR-2005 | – | Phase 1 | Intermediate and High-risk Non-muscle Invasive Bladder Cancer | Dec 2026 |
| SHR-1501 KRAS inhibitor | – | Phase 1 | High-risk NMIBC; Patients With Advanced or Metastatic Malignant Tumors | May 2027 |
| HRS-4642 | – | Phase 1 | Locally Advanced or Metastatic Pancreatic Cancer With | Oct 2027 |
| SHR-7367 Injection | – | Phase 1 | Solid Tumor | Dec 2027 |
| SHR-3836 | – | Phase 1 | Multiple Myeloma | Apr 2028 |
| SHR-9839 for Injection | – | Phase 1 | Advanced Solid Tumor; Advanced Solid Tumors | Jun 2029 |
| SHR-A1921 for Injection | – | Phase 1 | Advanced Solid Tumors | Jun 2029 |
| SHR-A2009 for Injection | – | Phase 1 | Advanced Solid Tumors | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05701709 | SHR-A2102 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2025 |
| NCT04877717 | SHR-A1904 | Phase 1 | Advanced Solid Cancer | Oncology | Dec 2025 |
| NCT05836948 | SHR-9839 for Injection | Phase 1 | Advanced Solid Tumor | Oncology | May 2026 |
| NCT06512051 | Adebrelimab (SHR-1316) | Phase 1 | Advanced or Metastatic Non-small Cell Lung Cancer | Oncology | Oct 2026 |
| NCT06512051 | SHR-A2102 for Injection | Phase 1 | Advanced or Metastatic Non-small Cell Lung Cancer | Oncology | Oct 2026 |
| NCT06605222 | SHR-7787 Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT04993430 | HRS8807 | Phase 1 | ER-Positive, HER2-Negative Breast Cancer | Oncology | Dec 2026 |
| NCT04993430 | SHR6390 | Phase 1 | ER-Positive, HER2-Negative Breast Cancer | Oncology | Dec 2026 |
| NCT06108492 | SHR-2005 | Phase 1 | Intermediate and High-risk Non-muscle Invasive Bladder Cancer | Oncology | Dec 2026 |
| NCT05410730 | SHR-1501 | Phase 1 | High-risk NMIBC | Oncology | May 2027 |
| NCT06639347 | SHR-A2102 for Injection | Phase 1 | Advanced Urothelial Carcinoma | Oncology | May 2027 |
| NCT06738251 | SHR-A2102 for Injection | Phase 3 | Advanced Urothelial Carcinoma | Oncology | Sep 2027 |
| NCT06649292 | SHR-A1904 | Phase 3 | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Sep 2027 |
| NCT07296341 | Adebrelimab (SHR-1316) | Phase 1 | Locally Advanced or Metastatic Pancreatic Cancer With | Oncology | Oct 2027 |
| NCT07296341 | HRS-4642 | Phase 1 | Locally Advanced or Metastatic Pancreatic Cancer With | Oncology | Oct 2027 |
| NCT07229586 | Adebrelimab (SHR-1316) | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT07073534 | Adebrelimab (SHR-1316) | Phase 1 | Patients With Advanced or Metastatic Malignant Tumors | Oncology | Dec 2027 |
| NCT07073534 | SHR-1501 | Phase 1 | Patients With Advanced or Metastatic Malignant Tumors | Oncology | Dec 2027 |
| NCT07229586 | SHR-7367 Injection | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT06350006 | SHR-A1904 | Phase 1 | CLDN18.2-positive Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT06350006 | Adebrelimab (SHR-1316) | Phase 1 | CLDN18.2-positive Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT07490613 | SHR-3836 | Phase 1 | Multiple Myeloma | Oncology | Apr 2028 |
| NCT07798947 | SHR-7787 Injection | Phase 2 | Limited-stage Small-cell Lung Cancer | Oncology | Dec 2028 |
| NCT07268040 | SHR-7787 Injection | Phase 2 | Malignant Solid Tumors | Oncology | Dec 2028 |
| NCT07798947 | Adebrelimab (SHR-1316) | Phase 2 | Limited-stage Small-cell Lung Cancer | Oncology | Dec 2028 |
| NCT07268040 | Adebrelimab (SHR-1316) | Phase 2 | Malignant Solid Tumors | Oncology | Dec 2028 |
| NCT06895928 | SHR-A2102 for Injection | Phase 2 | Advanced Solid Tumors | Oncology | Dec 2028 |
| NCT07268040 | BP102 Injection | Phase 2 | Malignant Solid Tumors | Oncology | Dec 2028 |
| NCT06474455 | Adebrelimab (SHR-1316) | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2029 |
| NCT06474455 | SHR-9839 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2029 |
| NCT06474455 | SHR-A1921 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2029 |
| NCT06474455 | SHR-A2009 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2029 |
| NCT07229729 | SHR-A2102 for Injection | Phase 2 | Non-small Cell Lung Cancer | Oncology | Oct 2029 |
| NCT06417554 | SHR-A2102 for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2031 |
Jiangsu Simcere Pharmaceutical Sichuan Kelun-Biotech Biopharmaceutical Shandong Suncadia Medicine Shenyang Sunshine Pharmaceutical Sichuan Baili Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.